The application relates to variants or muteins of tissue inhibitor of metalloproteinase 3 (TIMP-3), especially variants thereof where certain amino acid residues are substituted in order to introduce N-linked glycosylation sites (N-X-T or N-X-S). Some of the variants made improve the half-life and pharmacokinetic or pharmacodynamic properties and facilitate production and purification. In particular, the mutein contain the pairs: K45N/V47T； K50N/V52T； P56N/G58T； H78N/Q80T； K94N/E96T； D110N/K112T； the substitutions R138T； G173T and, optionally, also F57N, leading to at least two engineered N-linked glycosylation sites.
